LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC:VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves.
Financial Highlights for Q2 2024:
Revenue: ViaDerma maintained steady revenues of $300,191 for the first half of 2024, compared to $300,230 for the same period in 2023, showing resilience in its sales despite challenging market conditions.
Net Income: The company achieved a net income of $54,008 for the six-month period, a significant improvement from the net loss of $75,576 reported during the same period in 2023. This turnaround reflects a positive shift in profitability, representing a 171.5% increase in earnings.
Cash Reserves: Cash and cash equivalents surged to $826,175 as of June 30, 2024, ...
